Russell Lebovitz, Amprion CEO
October 8, 2024 11:24 AM EDTUpdated 06:17 PM
Financing
R&D

Ex­clu­sive: A small San Diego biotech wants to change how Parkin­son’s dis­ease is di­ag­nosed

Ryan Cross

Senior Science Correspondent

A pro­tein called al­pha-synu­cle­in that ac­cu­mu­lates and rav­ages the brains of some peo­ple with Parkin­son’s dis­ease is the tar­get of sev­er­al ex­per­i­men­tal drugs. Un­til re­cent­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

A service from the Financial Times